Fig 4.

(A) IFN enhances the antireplicon ability of BMS-790052. Replicon elimination assays were performed with H77c replicon cells at the indicated concentrations of BMS-790052 with or without pegIFN-α (4 ng/ml) for 7 or 14 days. Colonies formed from replicon-retaining cells following treatment were stained and photographed. (B) Inhibitor sensitivities of replicon cells recovered after 7 days of treatment with BMS-790052 in the presence or absence of IFN. Replicon cells recovered from a parallel set of tissue culture dishes to those described in Fig. 4A were used to determine the inhibitory activity of the indicated HCV inhibitors. EC₅₀s are plotted as the means ± standard deviations from two independent assays. The initial BMS-790052 concentration (conc.) is the concentration at which the cells were treated for 7 days prior to removing inhibitor and adding G418. IFN, pegIFN-α2a.